Julian Baker’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-668,000
Closed -$11.4M 138
2020
Q4
$11.4M Buy
+668,000
New +$8.37M 0.04% 70
2018
Q1
Sell
-19,247
Closed -$422K 123
2017
Q4
$422K Hold
19,247
﹤0.01% 117
2017
Q3
$787K Hold
19,247
0.01% 109
2017
Q2
$580K Hold
19,247
0.01% 111
2017
Q1
$696K Hold
19,247
0.01% 106
2016
Q4
$964K Hold
19,247
0.01% 109
2016
Q3
$1.01M Hold
19,247
0.01% 112
2016
Q2
$796K Hold
19,247
0.01% 121
2016
Q1
$782K Hold
19,247
0.01% 119
2015
Q4
$799K Hold
19,247
0.01% 123
2015
Q3
$296K Hold
19,247
﹤0.01% 130
2015
Q2
$478K Hold
19,247
﹤0.01% 122
2015
Q1
$440K Sell
19,247
-576
-3% -$14.5K ﹤0.01% 124
2014
Q4
$535K Hold
19,823
0.01% 116
2014
Q3
$233K Hold
19,823
﹤0.01% 106
2014
Q2
$308K Hold
19,823
﹤0.01% 103
2014
Q1
$390K Hold
19,823
0.01% 105
2013
Q4
$333K Buy
+19,823
New +$246K ﹤0.01% 92

Other funds holding FPRX

Julian Baker's FPRX Position: Q1 2021 in Review

Julian Baker sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 668,000 shares — an estimated $11.4M sold.

Julian Baker first reported a position in FPRX in Q4 2013 and held it in 18 quarters. The position peaked at $11.4M in Q4 2020. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

  • Julian Baker reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Julian Baker sold 668,000 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $11.4M.
  • Julian Baker first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 18 quarters.
  • Julian Baker's Five Prime Therapeutics, Inc. position peaked at $11.4M in Q4 2020.
  • 147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on Baker Bros. Advisors's 13F filing for Q1 2021, filed 17 May 2021.